GlassScriptPhysician profile
Celia M Herring
NPI 1821258435
$6,162.21
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,596 · 2022: $1,779 · 2023: $1,537 · 2024: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $578.25 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $559.55 | 2021-2024 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $488.27 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $468.28 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $386.89 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $373.58 | 2021-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $311.85 | 2021-2024 | |
| Vifor Pharma, INC. | $300.06 | 2021-2024 | Veltassa |
| Abbvie INC. | $284.80 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $200.01 | 2021-2023 | Gvoke Hypopen |
| Insulet Corporation | $158.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.60 | 2021-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $153.86 | 2023 | Korlym |
| Glaxosmithkline, LLC. | $150.92 | 2021-2024 | Benlysta, Shingrix, Arexvy |
| Aurinia Pharma U.S., INC. | $137.09 | 2022-2024 | Lupkynis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.